IDH2 and acute myeloid leukemia: The combination of venetoclax and enasidenib is under investigation in patients with IDH2-mutated myeloid malignancies in a phase Ib/II study (NCT04092179); preliminary results from 11 patients, mainly R/R AML, reported a CR + CRi rate of 55% with a tolerable toxicity profile [49].